Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Breast cancer Clinical Trials

Protocol Number Title
2009NTLS059
Methodology and Development of Tobacco Related Biomarkers Methodology and Development of Tobacco Related Biomarkers, part of 'Metabolism of Carcinogenic Tobacco-Specific Nitrosamines'
2009UC147
Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis (ISPY2)
2009UC147SS
2009UC147: SURMOUNT: Surveillance Markers of Utility for Recurrence after Neoadjuvant Therapy for Breast Cancer (Supplement 3 Sub-study to ISPY2)
2011NTLS081
Evaluating the Effectiveness of Reduced Nicotine Cigarettes, part of "Evaluating New Nicotine Standards for Cigarettes"
2013NTLS035
Vascular Assessment in Breast Cancer Survivors Taking Aromatase Inhibitors
2013NTLS041
A Device to Quantify Sweat of Single Sweat Glands to Diagnose Neuropathy
2013NTLS063
Mobile Phone Multimedia Messaging Intervention for Breast Cancer Screening: Intervention Phase
2013NTLS123
Quantitative Methods for Supplementing Contrast-Enhanced Magnetic Resonance Imaging of Breast Cancer.
2014IS044
Millenium C31001: A phase 1b/2 study of safety and efficacy of MLN0128 (Dual TORC 1/2 Inhibitor) in combination with exemestane or fulvestrant therapy in postmenopausal women with ER+/HER2- advanced or metastatic breast cancer that has progressed on treatment with everolimus in combination with exemestane or fulvestrant
2014NTLS052
Pilot Study of Clone 6 scFv As a Novel Marker for Isolation and Characterization of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer and Bladder Cancer
2015IS008
Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients with Hormone Receptor Positive, HER2-normal Primary Breast Cancer with High Relapse Risk after Neoadjuvant Chemotherapy (Penelope)
2015IS111
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
2015NTLS026
Aromatase Inhibitors and Vascular Health
2016IS065
An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts
2016IS069
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects with Advanced Malignancies
2016UC078
A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016
EAY131-Z1C
EAY131-Z1C: MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC

17 trials displayed